trending Market Intelligence /marketintelligence/en/news-insights/trending/6cCWipz788wfQbF8mUsy5w2 content esgSubNav
In This List

Brazil places $24M order for Protalix's Gaucher disease treatment

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Brazil places $24M order for Protalix's Gaucher disease treatment

Brazil's Ministry of Health placed a $24 million order for Alfataliglicerase with Protalix BioTherapeutics Inc. to treat Gaucher patients in the country.

The company will deliver the drug in three shipments by the end of next year.

The order comes at a time when the company is pushing for Alfataliglicerase to become the preferred therapy for Brazilian Gaucher patients.